Who is sponsoring NCT05663177?

NCT05663177 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT05663177?

Interventions in NCT05663177: Almonertinib and metronomic oral vinorelbine.

What condition does NCT05663177 study?

NCT05663177 studies EGFR, NSCLC, Third-generation TKI.

Is NCT05663177 still recruiting?

NCT05663177 is currently status unknown. Last updated 23 December 2022.

Last reviewed 2022-12-23 · How we verify

NCT05663177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Almonertinib Plus Metronomic Oral Vinorelbine

Status unknown Last updated 23 December 2022

What this trial tests

trial testing Almonertinib and metronomic oral vinorelbine in EGFR in 40 participants. Status unknown.

Timeline

20 December 2022

Primary endpoint
20 December 2023

1 June 2024

Quick facts

Lead sponsor	Fujian Cancer Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	20 December 2022
Primary completion	20 December 2023
Estimated completion	1 June 2024

Drugs / interventions tested

Almonertinib and metronomic oral vinorelbine — full drug profile →

Conditions studied

EGFR — all drugs for EGFR →
NSCLC — all drugs for NSCLC →
Third-generation TKI — all drugs for Third-generation TKI →

Sponsor

Fujian Cancer Hospital

Who can join

18 and older, any sex, with EGFR or NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for EGFR

Currently open trials in the same condition.

NCT07128199 — A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Sta · Phase 3 · recruiting
NCT07303218 — The HER Project: HRD in EGFR-mutated NSCLC · active not recruiting
NCT06755684 — Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR · Phase 2 · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05663177 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 23 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05663177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing